Le Lézard
Classified in: Health
Subjects: AWD, NPT, SVY

Pancreatic Cancer Action Network Awarded Highest Four-Star Rating From Leading Nonprofit Evaluator For 15th Consecutive Year


MANHATTAN BEACH, Calif., Aug. 14, 2019 /PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), a leading patient advocacy organization, announced today that it has earned a four-star rating from Charity Navigator for the 15th consecutive year. While approximately 40 percent of all nonprofits evaluated by Charity Navigator receive four-star ratings, only .26 percent, or a total of 23 organizations out of the more than 9,100 rated, have received this rating with the same consistency as PanCAN, according to a representative from Charity Navigator.

PanCAN has received the highest rating from Charity Navigator for 15 consecutive years.

Charity Navigator evaluates nonprofit organizations using an objective, data-driven approach analyzing a company's financial health as well as accountability and transparency. A four-star rating identifies an organization that exceeds industry standards in these areas and outperforms most charities in its cause. The rating is designed to provide a reliable, third-party assessment of an organization to potential donors.

"It is an honor to, once again, have PanCAN be recognized with a four-star rating from Charity Navigator," said Julie Fleshman, JD, MBA, president and CEO of PanCAN. "We are committed to openness and transparency with how we steward the dollars of our generous donors and remain steadfast in our mission to improve outcomes for patients fighting the world's toughest cancer."

Funds raised help PanCAN fund research and provide numerous patient and clinical services, including its Know Your Tumor® precision medicine service, the Patient Registry, Research Grants Program and Clinical Trial Finder.

PanCAN speaks with more pancreatic cancer patients than any other organization in the world, offering patients and caregivers one-to-one, personalized support and resources, including information about clinical trials, through its Patient Central service. Through its Healthcare Professional Services, the healthcare professional community can access free, personalized support for anything related to pancreatic cancer at 877-2-PANCAN.

To learn more, visit pancan.org and follow along on TwitterInstagram and Facebook.

About the Pancreatic Cancer Action Network
The Pancreatic Cancer Action Network (PanCAN) is dedicated to fighting the world's toughest cancer. In our urgent mission to save lives, we attack pancreatic cancer on all fronts: research, clinical initiatives, patient services and advocacy. Our effort is amplified by a nationwide network of grassroots support. We are determined to improve patient outcomes today and to double pancreatic cancer survival.

Media Contact:
Jillian Scholten
Senior Manager, Public Relations
Pancreatic Cancer Action Network
Phone: 949-244-2561
Email: [email protected]

The Pancreatic Cancer Action Network (PanCAN) is dedicated to fighting the world's toughest cancer. In our urgent mission to save lives, we attack pancreatic cancer on all fronts: research, clinical initiatives, patient services and advocacy. Our effort is amplified by a nationwide network of grassroots support. We are determined to improve outcomes today and to double survival by 2020. (PRNewsfoto/Pancreatic Cancer Action Network)

SOURCE Pancreatic Cancer Action Network


These press releases may also interest you

at 16:15
Medpace Holdings, Inc. ("Medpace") today announced that it will report its first quarter 2024 financial results after the market close on Monday, April 22, 2024. The Company will host a conference call the following morning, Tuesday, April 23, 2024,...

at 16:15
  Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell...

at 16:10
Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company"), a global pharmaceutical company, today announced that Chirag and Chintu Patel, Co-founders and Co-Chief Executive Officers, will ring the Nasdaq closing bell on Tuesday, April 2, 2024. "As...

at 16:10
ENDRA Life Sciences Inc. , a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reports financial results for the three months and year ended December 31, 2023 and provides a business update. Highlights from the fourth quarter of 2023...

at 16:08
Today, MPOWERHealth, a pioneer in the field of intraoperative neuromonitoring (IONM), announced the strategic acquisition of Assure Neuromonitoring's operations in pivotal markets, marking a significant step in expanding its best-in-class...

at 16:05
Immunome, Inc. , a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2023, and provided an overview of recent developments....



News published on and distributed by: